# Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

> **NCT04232423** · PHASE3 · COMPLETED · sponsor: **Department of Medical Services Ministry of Public Health of Thailand** · enrollment: 90 (actual)

## Conditions studied

- Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis

## Interventions

- **DRUG:** Olanzapine 10 Mg ORAL TABLET
- **DRUG:** Olanzapine 5 Mg ORAL TABLET
- **DRUG:** Placebo ORAL TABLET

## Key facts

- **NCT ID:** NCT04232423
- **Lead sponsor:** Department of Medical Services Ministry of Public Health of Thailand
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232423, "Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04232423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*